Keino H, Watanabe T, Nakayama M, et al. - Researchers conducted the study for assessing long-term effectiveness of infliximab (IFX) in refractory uveoretinitis associated with Behçet’s disease (BD) depending on uveoretinitis duration. Records of 16 patients with BD (32 eyes) followed for >5 years after starting IFX have been reviewed retrospectively. Long-term efficacy was contrasted between patients with short duration (≤ 18 months, n = 7) vs long duration (>18 months, n = 9) of their uveoretinitis prior to starting IFX. After starting IFX, the median follow-up was 132 months (76–146 months). The initiation of IFX therapy in BD patients within 18 months of their onset of uveoretinitis was more effective than after 18 months in maintaining good BCVA.